H Lundbeck Extends Rave EDC, CDM Agreement With Medidata Solutions
Medidata Solutions said that Rave was selected by H Lundbeck initially in 2007 as an EDC system based on its ability to handle large and complex studies and
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.